BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Stelara (ustekinumab) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Stelara (ustekinumab)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06520397-6@assetmemo.bio
DTSTAMP:20261121T005650Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Stelara (ustekinumab): Phase 4 readout est. (NCT06520397)
DESCRIPTION:Stelara (ustekinumab)\, phase 4\, Crohn's Disease.\nStudy: Effi
 cacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab
  Versus Intensified Ustekinumab Therapy in Crohn's Disease\nEstimated prim
 ary completion: 31 December 2026. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/ustekinumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06520397
URL:https://assetmemo.bio/drug/ustekinumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05270733-6@assetmemo.bio
DTSTAMP:20261121T005650Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Stelara (ustekinumab): Phase 4 readout est. (NCT05270733)
DESCRIPTION:Stelara (ustekinumab)\, phase 4\, Psoriasis.\nStudy: Developmen
 t of Predictive Psoriasis Response Endotypes Using Single Cell Transcripto
 mics\nEstimated primary completion: 31 December 2026. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/ustekinumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05270733
URL:https://assetmemo.bio/drug/ustekinumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05535738-6@assetmemo.bio
DTSTAMP:20261121T005650Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Stelara (ustekinumab): Phase 2/3 readout est. (NCT05535738)
DESCRIPTION:Stelara (ustekinumab)\, phase 2/3.\nStudy: Using a Contact Derm
 atitis Model With Biologic Medications to Study Skin Inflammation\nEstimat
 ed primary completion: 1 January 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/ustekinumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05535738
URL:https://assetmemo.bio/drug/ustekinumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06807593-6@assetmemo.bio
DTSTAMP:20261121T005650Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Stelara (ustekinumab): Phase 2 readout est. (NCT06807593)
DESCRIPTION:Stelara (ustekinumab)\, phase 2.\nStudy: Treatment of Immune Ch
 eckpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Ca
 ncer Patients\nEstimated primary completion: 31 March 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/ustekinumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06807593
URL:https://assetmemo.bio/drug/ustekinumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07303686-6@assetmemo.bio
DTSTAMP:20261121T005650Z
DTSTART;VALUE=DATE:20270415
DTEND;VALUE=DATE:20270416
SUMMARY:Stelara (ustekinumab): Phase 4 readout est. (NCT07303686)
DESCRIPTION:Stelara (ustekinumab)\, phase 4\, Ulcerative Colitis.\nStudy: D
 e-escalation of Ustekinumab Therapy in Patients With Crohn's Disease and U
 lcerative Colitis\nEstimated primary completion: 15 April 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/ustekinumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07303686
URL:https://assetmemo.bio/drug/ustekinumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06045754-6@assetmemo.bio
DTSTAMP:20261121T005650Z
DTSTART;VALUE=DATE:20270628
DTEND;VALUE=DATE:20270629
SUMMARY:Stelara (ustekinumab): Phase 4 readout est. (NCT06045754)
DESCRIPTION:Stelara (ustekinumab)\, phase 4\, Crohn's Disease.\nStudy: A St
 udy of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Uste
 kinumab in Adults With Crohn's Disease\nEstimated primary completion: 28 J
 une 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ustekinumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT060
 45754
URL:https://assetmemo.bio/drug/ustekinumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05092269-6@assetmemo.bio
DTSTAMP:20261121T005650Z
DTSTART;VALUE=DATE:20270929
DTEND;VALUE=DATE:20270930
SUMMARY:Stelara (ustekinumab): Phase 3 readout est. (NCT05092269)
DESCRIPTION:Stelara (ustekinumab)\, phase 3\, Ulcerative Colitis.\nStudy: A
  Long-term Extension Study of Ustekinumab in Pediatric Participants\nEstim
 ated primary completion: 29 September 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/ustekinumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05092269
URL:https://assetmemo.bio/drug/ustekinumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07529236-6@assetmemo.bio
DTSTAMP:20261121T005650Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Stelara (ustekinumab): Phase na readout est. (NCT07529236)
DESCRIPTION:Stelara (ustekinumab)\, phase na\, Ulcerative Colitis.\nStudy: 
 Digestive Evolution of Children With Crohn's Disease or Ulcerative Colitis
  Whose Anti-TNFα Treatment Was Switched to Ustekinumab Due to Paradoxical
  Psoriasis\,\nEstimated primary completion: 1 October 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/ustekinumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07529236
URL:https://assetmemo.bio/drug/ustekinumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06788340-6@assetmemo.bio
DTSTAMP:20261121T005650Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Stelara (ustekinumab): Phase 4 readout est. (NCT06788340)
DESCRIPTION:Stelara (ustekinumab)\, phase 4\, Ulcerative Colitis.\nStudy: M
 Odel-Informed Precision Dosing of Ustekinumab and VEdolizumab in Inflammat
 ory Bowel Disease\nEstimated primary completion: 30 December 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/ustekinumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06788340
URL:https://assetmemo.bio/drug/ustekinumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07138898-6@assetmemo.bio
DTSTAMP:20261121T005650Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Stelara (ustekinumab): Phase 2 readout est. (NCT07138898)
DESCRIPTION:Stelara (ustekinumab)\, phase 2.\nStudy: Immunosuppressant Mana
 gement in Rheumatology Patients Undergoing Elective Total Shoulder Arthrop
 lasty\nEstimated primary completion: January 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/ustekinumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07138898
URL:https://assetmemo.bio/drug/ustekinumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07268534-6@assetmemo.bio
DTSTAMP:20261121T005650Z
DTSTART;VALUE=DATE:20291101
DTEND;VALUE=DATE:20291102
SUMMARY:Stelara (ustekinumab): Phase 2 readout est. (NCT07268534)
DESCRIPTION:Stelara (ustekinumab)\, phase 2.\nStudy: Biologics in Folliculi
 tis Decalvans : an Adaptative Trial Research\nEstimated primary completion
 : 1 November 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/us
 tekinumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07268534
URL:https://assetmemo.bio/drug/ustekinumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07352566-6@assetmemo.bio
DTSTAMP:20261121T005650Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Stelara (ustekinumab): Phase 4 readout est. (NCT07352566)
DESCRIPTION:Stelara (ustekinumab)\, phase 4\, Psoriasis.\nStudy: Utilizatio
 n of a Microdevice for Psoriasis and Atopic Dermatitis\nEstimated primary 
 completion: 1 June 2030. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/ustekinumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07352566
URL:https://assetmemo.bio/drug/ustekinumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07576452-6@assetmemo.bio
DTSTAMP:20261121T005650Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Stelara (ustekinumab): Phase 4 readout est. (NCT07576452)
DESCRIPTION:Stelara (ustekinumab)\, phase 4\, Ulcerative Colitis.\nStudy: F
 irST Lines of Biologics in pAtients With ulceRaTivE Colitis: a Randomised 
 Controlled Trial\nEstimated primary completion: 1 June 2030. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/ustekinumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07576452
URL:https://assetmemo.bio/drug/ustekinumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
